Novo Nordisk slashes direct-to-consumer prices for Wegovy and Ozempic, offering new cash-paying patients temporary introductory offer of $199 per month for first two months. Trump administration deals with Novo Nordisk and Eli Lilly to make GLP-1 drugs more affordable, introducing Medicare coverage for obesity drugs on new TrumpRx website. Eli Lilly lowers prices by $50 on LillyDirect platform.

Read more at NBC Universal: Novo Nordisk cuts cash prices for Wegovy, Ozempic